PMC7450917_01
Magnetic resonance images of the brain (T1 axial postcontrast series) (A) before and (B) 1 month after treatment with lorlatinib, showing significant response of all metastatic brain lesions.
PO.19.00013f1.jpg
PMC7450917_01_PO.19.00013f1.jpg
f1
Lorlatinib induced a dramatic response in the brain and the systemic disease sites, evident in the first disease evaluation with imaging studies (Fig 1).
Timeline of the clinical course, highlighting the treatment interventions and the molecular data from the time of diagnosis. cfDNA, circulating cell-free DNA; SAR, stereotactic ablative radiation.
PO.19.00013f2.jpg
PMC7450917_01_PO.19.00013f2.jpg
f2
Disease remains in control 6 months later, while the patient continues receiving lorlatinib (Fig 2).